XFiPS-F44-3F-2
ESi032-A
General#
Cell Line |
|
| hPSCreg Name | ESi032-A |
| Alternative name(s) |
XFiPS-F44-3F-2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator | Spanish Stem Cell Bank (ES) |
| Owner | Centre of Regenerative Medicine in Barcelona - Banc de Linies Cellulars (CRMB) |
| Distributors | |
| Derivation country | Spain |
External Databases |
|
| Cellosaurus | CVCL_C107 |
General Information |
|
| Publications | |
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research: allowed
Clinical: not allowed
Commercial: not allowed
|
Donor Information#
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 1-4 |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Ethics#
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | No |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: |
| Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? | No |
| If you do not hold the SIGNED Donor Consent Form, do you know who does? | No |
| Contact information / weblink |
| If you do not hold the SIGNED Donor Consent Form, have you obtained a copy of the unsigned Donor Consent Form from the holder? | Yes |
| Alternatives to consent |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project |
| Does consent permit unforeseen future research, without further consent? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | No |
| Does consent expressly permit collection of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| How may genetic information associated with the cell line be accessed? |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | No |
| Please describe how access is provided: |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Contact data, institution, or website: |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Board of the Center of Regenerative Medicine in Barcelona |
| Approval number |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethics Board of the Center of Regenerative Medicine in Barcelona |
| Approval number |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Please describe: |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Further constraints on use |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
| Constraints for use or distribution |
hIPSC Derivation#
General |
|
| Source cell type |
foreskin fibroblastFibroblast from foreskin.
Synonyms
|
| Source cell origin |
prepuce of penisA retractable double-layered fold of skin and mucous membrane that covers the glans penis and protects the urinary meatus when the penis is not erect.
Synonyms
|
| Age of donor (at collection) | 1-4 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Yes |
| Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | morphological |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Gelatin | |||||||||
| Feeder cells |
Human foreskin fibroblasts Cellfinder Ont Id: CELDA_000001419 |
|||||||||
| O2 Concentration | 20 % | |||||||||
| CO2 Concentration | 5 % | |||||||||
| Medium |
Other medium:
Base medium: Knockout-DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| SOX2 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| ASA |
Yes |
| SMA |
Yes |
| GATA4 |
Yes |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XY
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.